Alzheimer ‘s disease – Page 4

Roche Advances Alzheimer’s Disease Diagnosis with Breakthrough Blood Test

10 months ago talkbio0Tagged Alzheimer 's disease, Amyloid, Diagnosis, Eli, Eli Lilly, Identifier, Medical Devices, Pathology, Roche, Roche (company), United States Food and Drug Administration

Alzheimer’s disease, blood test, Roche, Eli Lilly, FDA breakthrough device designation, pTau217, amyloid pathology, early diagnosis.

Sinaptica’s Neuromodulation Therapy Demonstrates 44% Reduction in Alzheimer’s Disease Progression

10 months ago talkbio0Tagged Alzheimer 's disease, Default Mode Network, Disease Progression, neuromodulation therapy, Non-invasive therapy, Personalized Treatment, Sinaptica, Stimulation procedure, Structure of precuneus

Sinaptica Therapeutics, Neuromodulation therapy, Alzheimer’s disease, Disease progression reduction, Personalized treatment, Non-invasive therapy, Default Mode Network (DMN), Precuneus stimulation

Leqembi’s Global Sales Reach $67 Million, Yet US Adoption Faces Hurdles

10 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Biogen, Eisai, global sales, Leqembi, U.S.

Leqembi, Biogen, Eisai, Alzheimer’s disease, global sales, US adoption challenges

Coya Therapeutics Faces Setback as COYA 302 Delivers Mixed Results in Mid-Stage Study for Frontotemporal Dementia

10 months ago talkbio0Tagged Alzheimer 's disease, Biotechnology, Clinical Trials, COYA, Neurodegenerative Disorders, Pick Disease of the Brain

Coya Therapeutics, COYA 302, Frontotemporal Dementia, Alzheimer’s Disease, Neurodegenerative Diseases, Clinical Trials, Biotechnology

Lexeo Therapeutics Unveils Promising Interim Data for LX1001 Gene Therapy in APOE4-Associated Alzheimer’s Disease

10 months ago talkbio0Tagged Alzheimer 's disease, Apolipoprotein E2, Apolipoprotein E4, Clinical Trials, gene therapy, Lexeo, Phase 1/2

Lexeo Therapeutics, LX1001, Gene Therapy, Alzheimer’s Disease, APOE4, APOE2, Clinical Trial, Phase 1/2

Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

10 months ago talkbio0Tagged Alzheimer 's disease, ARIA-E, Cerebral Edema, Changing, dosing, Eli, Eli Lilly, Kisunla, Risk, Treatment Protocols

Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction

Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling

10 months ago talkbio0Tagged Alzheimer 's disease, amyloid-related imaging abnormalities, ARIA-E, Cerebral Edema, Changing, Donanemab, dosing, Eli, Eli Lilly, Kisunla, oedema/effusion, TRAILBLAZER-ALZ, Treatment Protocols, Trial Phase 3B

Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

10 months ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition